Details on the length of hospital stay, the rate of hospital readmission within 100 day after transplant, antibiotic treatment’s characteristics of the first episode of FN, and the frequency of subsequent bloodstream infection in ASCT cohort
| . | LEVO-group . | NO-LEVO-group . | P value . |
|---|---|---|---|
| Duration of hospitalization (d) | 19 (15-27) | 17 (15-27) | .379 |
| Health care use (rehospitalization within 100 d from transplant) | 1 (3.2%)∗ | 3 (3.3%)† | .999 |
| Broad-spectrum antibiotics at the onset of the first FN episode | .026 | ||
| Ceftazidime | 1 (3.7%) | 0 (0%) | |
| Meropenem | 4 (14.8%) | 7 (9.5%) | |
| Piperacillin/tazobactam | 18 (66.7%) | 65 (87.8%) | |
| Others | 4 (14.8%) | 2 (2.7%) | |
| Escalation approach, yes | 12 (44.4%) | 34 (46.0%) | .999 |
| Days to antibiotic escalation since the onset of the first FN episode | 3 (2-3.5) | 2 (2-4) | .990 |
| Type of antibiotic escalation‡ | .345 | ||
| Vancomycin or daptomycin addition | 5 (41.7%) | 25 (73.5%) | |
| Amikacin or gentamycin addition | 0 (0%) | 0 (0%) | |
| Escalation to carbapenem | 7 (58.3%) | 18 (52.9%) | |
| Duration of antibiotic therapy to treat the first FN episode (d) | 9 (7-14) | 10 (8-14) | .645 |
| Reason of antibiotic therapy stop | 1.000 | ||
| Discontinuation (still in aplasia or after engraftment) | 24 (96.0%) | 66 (94.3%) | |
| Escalation for a second FN episode | 1 (4.0%) | 4 (5.7%) | |
| C difficile infection within 100 d | 0 (0%) | 2 (2.0%) | NA |
| ESBL-producing bacteria BSI within 100 d since transplant | 0 (0%) | 0 (0%) | NA |
| CR-GNB BSI within 100 d since transplant | 0 (0%) | 0 (0%) | NA |
| . | LEVO-group . | NO-LEVO-group . | P value . |
|---|---|---|---|
| Duration of hospitalization (d) | 19 (15-27) | 17 (15-27) | .379 |
| Health care use (rehospitalization within 100 d from transplant) | 1 (3.2%)∗ | 3 (3.3%)† | .999 |
| Broad-spectrum antibiotics at the onset of the first FN episode | .026 | ||
| Ceftazidime | 1 (3.7%) | 0 (0%) | |
| Meropenem | 4 (14.8%) | 7 (9.5%) | |
| Piperacillin/tazobactam | 18 (66.7%) | 65 (87.8%) | |
| Others | 4 (14.8%) | 2 (2.7%) | |
| Escalation approach, yes | 12 (44.4%) | 34 (46.0%) | .999 |
| Days to antibiotic escalation since the onset of the first FN episode | 3 (2-3.5) | 2 (2-4) | .990 |
| Type of antibiotic escalation‡ | .345 | ||
| Vancomycin or daptomycin addition | 5 (41.7%) | 25 (73.5%) | |
| Amikacin or gentamycin addition | 0 (0%) | 0 (0%) | |
| Escalation to carbapenem | 7 (58.3%) | 18 (52.9%) | |
| Duration of antibiotic therapy to treat the first FN episode (d) | 9 (7-14) | 10 (8-14) | .645 |
| Reason of antibiotic therapy stop | 1.000 | ||
| Discontinuation (still in aplasia or after engraftment) | 24 (96.0%) | 66 (94.3%) | |
| Escalation for a second FN episode | 1 (4.0%) | 4 (5.7%) | |
| C difficile infection within 100 d | 0 (0%) | 2 (2.0%) | NA |
| ESBL-producing bacteria BSI within 100 d since transplant | 0 (0%) | 0 (0%) | NA |
| CR-GNB BSI within 100 d since transplant | 0 (0%) | 0 (0%) | NA |
Results reported as median (IQR) or frequency (%); comparisons by Wilcoxon rank-sum test or χ2 or Fisher exact test.
Reasons for rehospitalization: neuromotor rehabilitation 1.
Reasons for rehospitalization: pulmonary complications 2 (1 pneumonia and 1 pulmonary thromboembolism), disease progression 1.
Description of antibiotic escalation in supplemental Table 1.